Post by Formycon AG

9,801 followers

๐…๐จ๐ซ๐ฆ๐ฒ๐œ๐จ๐ง'๐ฌ ๐€๐Ÿ๐ฅ๐ข๐›๐ž๐ซ๐œ๐ž๐ฉ๐ญ ๐๐ข๐จ๐ฌ๐ข๐ฆ๐ข๐ฅ๐š๐ซ๐ฌ ๐ฅ๐š๐ฎ๐ง๐œ๐ก๐ž๐ ๐ข๐ง ๐„๐ฎ๐ซ๐จ๐ฉ๐ž With the #launch of Ahzantiveยฎ and Baiamaยฎ by our commercialization partners, three Formycon biosimilars are now commercially available. โ€œThis is another important #milestone in scaling our #portfolio commercially,โ€ emphasizes Formycon CBO Nicola Mikulcik. In line with our #FYB4Growth strategy, we are relying on several strong commercialization partners to position the biosimilars broadly across the European #market landscape. Further information is available in our corporate news released today: https://lnkd.in/dxWQ7WK3 #TeamFormycon #Biosimilars #Ophtha #AMD #Aflibercept

Post content